A5056573159- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Screening and Detection
- Gallbladder and Bile Duct Disorders
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Neuroblastoma Research and Treatments
- Metastasis and carcinoma case studies
- Radiomics and Machine Learning in Medical Imaging
- Gastrointestinal disorders and treatments
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Anorectal Disease Treatments and Outcomes
- Cancer Immunotherapy and Biomarkers
Homi Bhabha National Institute
2018-2025
Tata Memorial Hospital
2016-2025
Copenhagen University Hospital
2023
Gentofte Hospital
2023
Bhabha Atomic Research Centre
2016
Tata Medical Center
2016
Creative Research Enterprises (United States)
2016
Yahoo (United Kingdom)
2014
Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College
2008-2009
Background: Little is known about the comprehensive geriatric assessment (CGA) profile of Indian patients. We aimed to describe CGA results oncology patients and identify incidence polypharmacy. Methods: The study a retrospective analysis data collected in clinic at Tata Memorial Hospital, tertiary cancer hospital India. Patients aged 60 years over with malignancy were evaluated. baseline social, demographic, disease details recorded. All underwent CGA, which domains nutrition, function...
PURPOSE Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 4%-16% of biliary tract cancers (BTCs). We aimed to evaluate the clinical activity gemcitabine-cisplatin (GC) plus anti-HER2 antibody trastuzumab as initial treatment HER2-positive BTCs. METHODS This study was an investigator-initiated, open-label, single-arm, multi-institutional, phase II trial adult patients with (defined immunohistochemistry [IHC] 3+ or IHC 2+ and fluorescent situ hybridization–positive),...
We assessed <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in the neoadjuvant setting patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). also evaluated variables associated resectability of primary tumor after PRRT. <b>Methods:</b> This study included 57 GEP-NET who had a that was unresectable (because vascular involvement as defined using pancreatic ductal adenocarcinoma criteria National Comprehensive Cancer Network) and underwent without any...
Importance The Cancer Aging Research Group (CARG) toxicity score is used to assess risk in geriatric patients receiving chemotherapy. Objective primary aim was validate the CARG treated with curative intent chemotherapy predicting grade 3–5 toxicities. Design This a longitudinal prospective observational study. Setting Tata Memorial Hospital, Mumbai, India, tertiary cancer care referral centre. Participants Patients, aged ≥65 years, gastrointestinal, breast or gynaecological stage I–III...
To assess the performance of Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic gastroenteropancreatic neuroendocrine tumor (GEP-NET) and correlate it with primary site, proliferation index, dual tracer imaging characteristics.Fifty patients (M : F 33 17, age: 26-71 years) histopathologically confirmed metastatic/inoperable NETs who had undergone at least three cycles PRRT were included analysis. As part pretreatment evaluation, they underwent either Tc-HYNIC TOC...
Abstract Background There is limited data on outcomes in cancer patients with coronavirus disease 2019 (COVID‐19) from lower middle‐income countries (LMICs). Patients and Methods This was an observational study, conducted between 12 April 10 June 2020 at Tata Memorial centre, Mumbai, undergoing systemic therapy laboratory confirmed COVID‐19. The objectives were to evaluate cumulative 30‐day all‐cause mortality, COVID‐19 attributable factors predicting time viral negativity after initial...
'Textbook Outcome' (TO) represents an effort to define a standardized, composite quality benchmark based on intraoperative and postoperative endpoints. This study aimed assess the applicability of TO as outcome measure following liver resection for hepatic neoplasms from low- middle-income economy determine its impact long-term survival. Based identified perioperative predictors, we developed validated nomogram-based scoring risk stratification system.
Objective There are limited data on the utility of TAS-102 plus bevacizumab in patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) treated India. Methods Patients diagnosed mCRC, defined as having received at least prior oxaliplatin and irinotecan–based chemotherapy between January 2017 2022, who began treatment a combination were retrospectively analyzed for demographic variables, survivals, prognostic parameters. The primary endpoint study was estimation median...
49 Background: Traditional testing in mCRC primarily focuses on RAS and RAF mutations. However, a broader range of emerging biomarkers, collectively termed the "Pressing panel" (PP), identifies patients with RAS/RAF wild-type (wt) tumors who may particularly benefit from anti-EGFR therapy. Comprehensive liquid biopsies provide non-invasive method for identifying traditional biomarkers. Limited genomic data, including prevalence PP alterations (alts), is available India tested by ctDNA NGS....
584 Background: HER2 overexpression or amplification is a therapeutic target of interest in advanced BTC, especially gallbladder cancers (GBC). Limited studies evaluate the role T-DM1 these groups cancers. Methods: This study was an investigator-initiated, open-label, single-arm, phase II trial patients (pts) aged 18 years older with HER2-positive (defined as IHC 3+ 2+, and FISH positive), BTCs who had previously received systemic therapy (irrespective prior additional targeted therapy). Pts...
Identifying therapeutic targets for Signet Ring Cell Carcinoma (SRCC) of the colon and rectum is a clinical challenge due to lack Patient-Derived Organoids (PDO) or Xenografts (PDX). We present robust method establish PDO PDX models answer address this unmet need. demonstrate that these identify novel strategies targeting therapy resistance peritoneal metastasis. derived nine from colorectal SRCC patients. Detailed histopathological characterization confirmed fidelity original tumors. Drug...
Aim Statins have been shown to improve the possibility of a pathological complete response (pCR) in patients with locally advanced rectal cancer when given combination neo-adjuvant chemo-radiation (NACTRT) observational studies. The primary objective this phase II randomized controlled trial (RCT) is determine impact rosuvastatin improving pCR rates who are undergoing NACTRT. secondary objectives compare adverse events, postoperative morbidity and mortality, disease-free survival (DFS),...
<p>Paclitaxel treatment does not lead to a reduction in tumor growth.</p>
<p>Characterization of mucin-high PDX models over the passage.</p>
<p>Drug toxicity testing in SRCC PDO models.</p>
<p>Drug toxicity testing on SRCC PDO models.</p>
<p>Drug toxicity testing in SRCC PDO models.</p>
<div>AbstractPurpose:<p>Identifying therapeutic targets for signet ring cell carcinoma (SRCC) of the colon and rectum is a clinical challenge because lack patient-derived organoids (PDO) or xenografts (PDX). To address this unmet need, we present robust method establishing PDO PDX models. We demonstrate that these models identify novel strategies targeting therapy resistance peritoneal metastasis.</p>Experimental Design:<p>We derived nine from patients with colorectal...
<p>Treatment of SRCC PDX (C1, C3, and R3) with FOLFIRI+ Paclitaxel or Vincristine reduced tumor volume.</p>